The only predictive biomarkers of response that can be used in clinical practice are the assessment of PD-L1 levels by immunohistochemistry (IHC), micro-satellite instability (MSI) and tumor mutational burden (TMB), though the latter only in the USA [4–7]. The gene discussed is CD274; the disease is neoplasm.